Phase 3
Completed N=39
Preoperative Alpha Blockade for Pheochromocytoma
Source: ClinicalTrials.gov NCT03176693 ↗Enrolled (actual)
39
Serious AEs
0.0%
Results posted
Nov 2023
Primary outcomePrimary: Hemodynamic Instability — 14; 13 percentage of total operative time — p=.56
◆ Published Evidence
Highly cited
183citations · ~8 / year
Efficacy and safety of doxazosin for perioperative management of patients with pheochromocytoma.
Summary
Pheochromocytoma is a rare, catecholamine (ex. adrenaline) secreting tumor that requires preoperative alpha blockade to minimize intraoperative hemodynamic instability, thereby reducing intra- and postoperative morbidity and mortality. Phenoxybenzamine is a non-selective alpha blocker that is significantly more expensive and is associated with increased adverse effects in comparison with selective alpha blockers such as doxazosin. Retrospective studies show minimal differences in hemodynamic instability and no differences in postoperative morbidity and mortality between selective vs. non-selective alpha blockers. This study is a randomized controlled trial that will compare hemodynamic instability, morbidity, mortality, cost, and quality of life between patients blocked with phenoxybenzamine vs. doxazosin.
Linked Publications (5)
-
Efficacy and safety of doxazosin for perioperative management of patients with pheochromocytoma.
-
Comparison of two preoperative medical management strategies for laparoscopic resection of pheochromocytoma.
-
Predictors of hemodynamic instability during surgery for pheochromocytoma.
-
Both preoperative alpha and calcium channel blockade impact intraoperative hemodynamic stability similarly in the management of pheochromocytoma.
-
Selective Versus Non-selective α-Blockade Prior to Laparoscopic Adrenalectomy for Pheochromocytoma.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Hemodynamic Instability |
14; 13 | .56 |
| SECONDARY Mortality |
0; 0 | — |
| SECONDARY Daily Cost of Drug |
442.20; 5.06 | — |
| SECONDARY Quality of Life- Physical Functioning, Role Limitations Due to Physical Problems, Bodily Pain, General Health Perceptions, Vitality, Social Functioning, Role-limitations Due to Emotional Problems, and Mental Health |
— | — |
| SECONDARY Morbidity as Assessed by Occurrence of Adverse Events |
0; 0 | — |
| SECONDARY Participants Admitted to Post-operative Intensive Care Unit (ICU) |
2; 1 | — |
Eligibility Criteria
Inclusion Criteria
- Adults with pheochromocytoma / paraganglioma undergoing surgical resection
Exclusion Criteria
- Children < 18 years
Data sourced from ClinicalTrials.gov (NCT03176693) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.